Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Isis' Balancing Act: Diversify With Cancer, But Avoid High-Stakes Gambles

Executive Summary

Isis tried a delicate balancing act during its May 20 pipeline update: it sought to accentuate its progress in branching out into cancer drug development, while also reassuring investors that its oncology spend is relatively modest and doesn't introduce major risk

You may also be interested in...

Isis Reacquires Cancer Compound From Lilly To Develop In-House

Lilly holds option to reacquire LY2275796 at the start of Phase III.

Mipomersen Brings Better-Than-Expected Phase III Results, But Some Questions Linger

Genzyme/Isis expect to file NDA for the cholesterol-lowering antisense drug in mid-2010.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts